The Washington University Alzheimer's Disease Research Center (ADRC) initiates, fosters, and supports the performance of innovative, cutting-edge research on Alzheimer's disease (AD) and related topics with regard to the etiology, pathogenesis, diagnosis, treatment, and prevention of disease. We provide well-characterized research participants (persons with AD and age-matched controls), their clinical, psychometric, and imaging data, and their tissue (blood, DNA, CSF, autopsy material) to research projects. We also provide intellectual and financial support to scientists at Washington University, at other Alzheimer's Centers, and the research community nationally and internationally and engage in formal and informal collaborations, including multi-disciplinary/multi-Center studies and the initiatives sponsored by the National Institute on Aging, the National Alzheimer Coordinating Center, and the National Cell Repository for Alzheimer's Disease. Historically, our Center has focused on the earliest stages of dementia to identify the initial clinical and pathologic changes that distinguish AD from normal aging. Our approach is balanced between clinicopathologic and basic science domains with emphasis on interdisciplinary efforts. We will continue our training of students, fellows and junior faculty in clinical and basic science research skills. We will continue to engage in outreach activities to transfer information on AD to lay and professional audiences. We have a commitment to underserved populations that are the focus of our African American and Rural Satellites and will continue activities that promote the inclusion of these populations in research. This competing renewal application includes six cores: A: Administration, B: Clinical, C: Data Management and Statistics, D: Neuropathology, E: Education and F: Genetics. There are two satellites: African American (Core B: Clinical) and Rural (Core E: Education). The ADRC resources contained in these Cores and Satellites will promote and advance AD-related research as represented by the three projects in this application: Project 1. Novel protein biomarkers for Alzheimer's disease in cerebrospinal fluid;(Richard Perrin) 2. Changing tau protein levels and tau protein isoforms in mouse models of dementia;(Timothy Miller) 3. APOE metabolism in AD and controls;(Randall Bateman).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005681-30
Application #
8459482
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
1997-06-15
Project End
2015-04-30
Budget Start
2013-06-01
Budget End
2014-04-30
Support Year
30
Fiscal Year
2013
Total Cost
$2,389,588
Indirect Cost
$788,973
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Ebbert, Mark T W; Staley, Lyndsay A; Parker, Joshua et al. (2016) Variants in CCL16 are associated with blood plasma and cerebrospinal fluid CCL16 protein levels. BMC Genomics 17 Suppl 3:437
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Staley, Lyndsay A; Ebbert, Mark T W; Bunker, Daniel et al. (2016) Variants in ACPP are associated with cerebrospinal fluid Prostatic Acid Phosphatase levels. BMC Genomics 17 Suppl 3:439
Lucey, Brendan P; Mcleland, Jennifer S; Toedebusch, Cristina D et al. (2016) Comparison of a single-channel EEG sleep study to polysomnography. J Sleep Res 25:625-635
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0152082
Gordon, Brian A; Blazey, Tyler; Su, Yi et al. (2016) Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. JAMA Neurol 73:1192-1200
Cummings, Jeffrey; Aisen, Paul S; DuBois, Bruno et al. (2016) Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther 8:39
Besser, Lilah M; Alosco, Michael L; Ramirez Gomez, Liliana et al. (2016) Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. J Neuropathol Exp Neurol 75:955-962
Saint-Aubert, Laure; Pariente, Jérémie; Dumas, Herve et al. (2016) Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man. BMC Neurol 16:122
Forrester, Sarah N; Gallo, Joseph J; Smith, Gwenn S et al. (2016) Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia. Am J Geriatr Psychiatry 24:117-25

Showing the most recent 10 out of 715 publications